Politicians from across the political spectrum are up in arms over healthcare giant Sanofi’s plans to sell France’s best-known medical drug Doliprane to US investors, a move critics say would lead to a “loss of sovereignty” for the country in a sensitive industry.
Related Posts
US Justice Department considers breaking up Google in search monopoly case
The US Justice Department has told a federal judge that it is mulling over recommending that Google be forced to sell parts of its operations, […]
‘Drill, baby, drill’: What Trump’s election victory means for climate change
Nations have gathered in Azerbaijan for COP29, under the shadow cast by the re-election of climate change denier Donald Trump, who has pledged to row […]
Russia’s attempt to end dollar dominance and bypass Western sanctions
At this year’s BRICS summit, one of the main issues on the agenda is Vladimir Putin’s idea for a payment system to rival SWIFT and bypass […]